Global Non-Hematological Cancers Market to 2021 - 18 of the top 20 Pharmaceutical Companies Will Market Non-hematological Cancer Drugs - Research and Markets

DUBLIN, May 12, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics" report to their offering.

The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%,

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient's tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Market drivers will include the increasing prevalence of cancer globally, and the introduction of more targeted treatments, which will improve the overall survival of poor-performance-status patients and enable more rounds of chemotherapy to be administered.

There are 2,954 non-hematological oncology products in active development, 171 of which are in Phase III development or Pre-registration,

Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021

- What is the generic penetration?

- Which drugs will achieve blockbuster status?

Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

- How does the composition of the pipeline compare with that of the existing market?

- What mechanisms of action are most common for pipeline drugs?

18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period

- How is their revenue share of the non-hematological cancer market set to change?

- What CAGR will these companies register in the forecast period?

Key Topics Covered:

1 Table of Contents 1.1 List of Tables 1.2 List of Figures

2 Introduction

2.1 Therapy Area Introduction

2.2 Symptoms

2.3 Etiology and Pathophysiology

2.3.1 Etiology

2.3.2 Pathophysiology

2.3.3 Tumor Initiation

2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality

2.3.5 Tumor Metabolic Shift

2.3.6 Tumor Progression, Invasion and Metastasis

2.3.7 Evasion of the Immune Response

2.3.8 Cancer Stem Cells

2.4 Co-morbidities and Complications

2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates

2.5.1 Breast Cancer

2.5.2 Colorectal Cancer

2.5.3 Lung Cancer

2.5.4 Prostate Cancer

2.6 Treatment

2.6.1 Surgery and Radiation Therapy

2.6.2 Chemotherapy

2.6.3 Hormonal Therapies

2.6.4 Targeted Therapies

3 Key Marketed Products

3.1 Overview

3.2 Avastin (bevacizumab)

3.3 Herceptin (trastuzumab)

3.4 Alimta (pemetrexed)

3.5 Zytiga (abiraterone acetate)

3.6 Xtandi (enzalutamide)

3.7 Perjeta (pertuzumab)

3.8 Tarceva (erlotinib hydrochloride)

3.9 Yervoy (ipilimumab)

3.10 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target

4.4.5 Conclusion

4.5 Assessment of Key Pipeline Products

4.5.1 Neratinib - Puma Biotechnology

4.5.2 AZD-4736 - AstraZeneca

4.5.3 LY2835219 - Eli Lilly

4.5.4 LEE-011 - Novartis

4.5.5 JNJ-56021927 - Johnson & Johnson

4.5.6 Tremelimumab - AstraZeneca

4.5.7 Margetuximab - Macrogenics

4.5.8 Conclusion

5 Multi-scenario Market Forecast to 2021

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target

5.3.1 Epidermal Growth Factor Receptors

5.3.2 Cyclin-Dependent Kinase 4 and 6

5.3.3 Programmed Cell Death Protein 1 Inhibitor

5.3.4 VEGF Inhibitors

5.3.5 ALK Tyrosine Kinase Receptor

5.3.6 Androgen Receptor Antagonists

5.4 Revenue and Market Share Analysis by Company

5.4.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset Avastin's and Herceptin's Patent Expiries?

5.4.2 Novartis - Markets Blockbuster Drugs, but How Much of These Revenues Are Related to Non-hematological Cancers?

5.4.3 Bristol-Myers - What Does Limited Product Selection for Non-hematological Cancers Mean for Revenues?

5.4.4 Pfizer - What Do Patent Expiries Mean for Pfizer?

5.4.5 Astellas - Tarceva's Expiry Effects

5.4.6 Amgen - Growth Despite Multiple Patent Expiries

6 Company Analysis and Positioning

6.1 Company Landscape

6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.1.1 Deals by Region, Year and Value

7.1.2 Deals by Stage of Development and Value

7.1.3 Deals by Molecule Type, Mechanism of Action and Value

7.1.4 Table for Licensing Deals Valued Above $100m

7.2 Co-development Deals

7.2.1 Deals by Region, Year and Value

7.2.2 Deals by Stage of Development and Value

7.2.3 Deals by Molecule Type, Mechanism of Action and Value

7.2.4 Table for Co-development Deals Valued Above $100m

8 Appendix

For more information visit http://www.researchandmarkets.com/research/9kpwxk/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]